Author: ltadmin

September 2, 2021

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the sale of the Domestic Appliances business to Hillhouse Investment, a global investment firm. The results of this transaction, which Philips announced on March 25, 2021, will be reported under discontinued operations in the third quarter of 2021. Philips received cash proceeds after tax and transaction-related costs of approximately EUR 3 billion.

The transaction values Domestic Appliances, a global leader with EUR 2.2 billion sales in 2020 in kitchen, coffee, garment care and home care appliances, at an enterprise value of approximately EUR 3.7 billion. The total deal value amounts to approximately EUR 4.4 billion resulting from an additional 15-year brand license agreement with annual payments that represent an estimated net present value of approximately EUR 0.7 billion.

“I am pleased that in line with our plans we have completed this transaction and concluded our major divestments,” said Frans van Houten, CEO of Royal Philips. “I am confident that the Domestic Appliances business will be able to expand on its market leadership with the support of Hillhouse Investment. In the past 12 months, Philips has further strengthened its portfolio with the launch of new products and solutions, as well as the acquisitions of Intact Vascular in image guided therapy, and BioTelemetry and Capsule Technologies in connected care. We are executing on our strategy to deliver integrated solutions that support professional healthcare customers achieve the Quadruple Aim and consumers with their health.”

“We are in a great position to continue bringing meaningful innovations to the consumer’s home in areas such as kitchen, coffee, garment care and home care appliances,” said Henk de Jong, CEO of Domestic Appliances. “We look forward to embark on this new partnership with Hillhouse Investment, building on our longstanding consumer, customer and partner relationships, as well as our market leading positions across our portfolio and the brand license partnership with Philips.”

Following the sale of Domestic Appliances, Philips’ EUR 3.2 billion Personal Health businesses will continue to shape its important role in the company’s integrated health continuum approach through products and solutions that support healthy living and prevention of diseases. Philips is a global leader in oral healthcare, personal care and mother & child care, areas that are essential building blocks of consumer health.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachments

• Philips SpeedPro Max
• Philips Airfryer XXL

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

—NDA supported by positive data from Phase 3 CHELATE clinical trial

— TETA 4-HCl previously granted Orphan Drug Designation for first-line treatment of Wilson’s Disease

Paris, France – 2 September 2021 – Orphalan SA, a Company that identifies, develops and delivers worldwide therapies for orphan diseases, today announces that the US Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the first-line treatment of Wilson’s Disease.

Wilson’s Disease is a rare inherited disorder of copper transport primarily affecting the liver and brain, affecting about 1 in every 30,000 people worldwide. TETA 4HCl is proposed as an alternative copper chelating agent to d-Penicillamine, the only approved first-line treatment of Wilson’s Disease for the last 70 years, to which about a third of patients develop intolerance.

The Company’s NDA submission follows its previous Orphan Drug Designation by the FDA. The filing is based upon positive data from the CHELATE Phase 3 clinical trial that met its primary efficacy endpoint by demonstrating that TETA 4HCl was non-inferior to d-Penicillamine as measured by copper speciation evaluation of non-ceruloplasmin copper (NCC).

Treatment with TETA 4HCl is supported by Orphalan’s novel NCC assay, for which the Company plans to file for FDA approval as a companion diagnostic. The in vitro NCC assay has the potential to provide an important additional tool to support physicians in identifying patients and monitoring their treatment with TETA 4HCl.

Dr Naseem Amin, Chief Executive Officer at Orphalan, commented: “The FDA’s acceptance of the NDA brings us one step closer to providing first–line treatment to patients with Wilson’s Disease, who currently do not benefit from alternative methods of treatment, beyond D-Penicillamine ”.

Notes to Editors

About the CHELATE Study

CHELATE was a Phase 3, multicentre, randomised, open label, active-controlled, non-inferiority study conducted in 9 countries at 15 centres designed to evaluate efficacy and safety of trientine tetrahydrochloride compared to d-Penicillamine in patients with stable Wilson’s Disease. Fifty-three adult Wilson’s Disease patients with clinically stable disease for over one year and who met specific inclusion criteria, including laboratory measures of serum non-ceruloplasmin copper (NCC), 24-hour urinary copper excretion (UCE) and liver function tests, were followed for a baseline period for 12 weeks before being randomised 1:1 to either trientine tetrahydrochloride or d-Penicillamine twice daily. The study’s primary endpoint was serum NCC as measured using Orphalan’s proprietary method using copper speciation at 24-weeks post-randomisation. A secondary composite efficacy endpoint was NCC and 24-hour UCE.

Additional secondary endpoints included were: clinical Global Impression of Change (CGIC) score; serum copper and ceruloplasmin levels; the unified Wilson’s Disease Rating Scale (UWDRS); modified Nazer score; cognitive assessments and standard safety assessments. In addition, an independent adjudication committee blinded to the allocated treatment, and study centres assessed key efficacy and safety parameters to determine clinical stability of the patient. Trientine tetrahydrochloride was well tolerated and during treatment, more patients achieved the pre-specified composite endpoint of NCC and 24-hour Urinary Copper Excretion (UCE) within therapeutic target ranges, compared to patients treated with d-Penicillamine, 50% versus 24%. Data from the trial was presented during an oral presentation at EASL’s The International Liver Congress™ 2021.

About Orphalan
At Orphalan, our mission is clear: we are pioneers in orphan diseases. Orphalan identifies, develops and delivers worldwide innovative therapies for people living with Orphan diseases. Orphalan was founded in 2011 and has launched Cuprior™ across Europe with its own commercial organisation. For more information, visit www.orphalan.health and follow us on LinkedIn.

For more information, please contact: 

Orphalan
Tel: +33 (0)1 42 49 82 64
info@orphalan.health

Consilium Strategic Communications: 
Mary-Jane Elliott, Allison Connolly, Genevieve Wilson
Tel: +44 (0) 203 709 5700
orphalan@consilium-comms.com

Sophia Bush, Martin Sheen, and Yalitza Aparicio Martínez to Join ILO Director Guy Ryder, Brid Gould of Sodexo, Saadia Zahidi of the World Economic Forum, and Sharan Burrow of ITUC on Stage with Workers

Worldwide, Sept. 01, 2021 (GLOBE NEWSWIRE) — Essential workers from North and South America, Europe, Africa and Asia will meet with global business and government leaders to discuss a framework for a just economic recovery from the COVID-19 pandemic in the first global summit of its kind Sept. 8-10.

Days before world representatives gather for the United Nations General Assembly, the Essential for Recovery Summit will center the demands of care workers and the 61% of workers worldwide who work in the informal economy, including domestic workers, agricultural workers, street vendors, and home-based workers.

• Click here for the full release in English, Spanish, French, Arabic and Hindi.
• Follow this link to register for the summit.

“Essential workers deserve more than our praise. They deserve our action. They have taken care of us—and ensured that others were fed and cared for—at great risk and cost to their lives, and now world leaders must take action to make sure it’s not just the privileged or well-connected who get to recover,” said Sophia Bush, a prominent American actress and social activist working to protect and advance women’s and girls’ rights globally, who will serve as the host of the event.

Despite the life-threatening disparities exposed by the COVID-19 pandemic, workers around the world continue to fight for their rights in the workplace: far too many workers continue to endure limited access to healthcare, lack of social protections, dangerous work conditions including exposure to COVID-19, and frequent harassment and violence while working.

In conversations with cultural influencers like Martin Sheen and Yalitza Aparicio Martínez, and powerhouse leaders of worker movements like Ai-jen Poo in the U.S., Myrtle Witbooi in South Africa, and Carmen Britez in Argentina, essential workers will discuss the necessity for an ambitious social contract that puts the wellbeing of workers at the heart of government spending and corporate behavior, rather than piecemeal interventions or austerity measures similar to those that followed the collapse of financial markets in 2008.

About Essential For Recovery:

The Essential for Recovery Summit is led by non-profit labor organizations — including HomeNet International, International Domestic Workers’ Federation, International Trade Union Confederation, Solidarity Center, StreetNet International, UNI Global Union, and Women in Informal Employment: Globalizing and Organizing — and supported by the Open Society Foundations.

Office of Communications
Open Society Foundations 
(212)-548-0378
media@opensocietyfoundations.org

PRESS RELEASE

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), September 1, 2021, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below.

Robelga SRL / Robert Taub

On August 27, 2021, Nyxoah received a transparency notification from Robelga SRL following the passive downward crossing by Robelga SRL of the 3% threshold on July 7, 2021. As of such date, Robelga SRL held 696,000 shares, representing 2.78% of the total number of voting rights on July 7, 2021 (25,002,609).

The notification dated August 27, 2021 contains the following information:

• •  Reason for the notification: passive crossing of a threshold
  •  Notification by: a parent undertaking or a controlling person
  •  Persons subject to the notification requirement: Robelga SRL (with address at Avenue Blücher 63, 1180 Uccle), BMI Estate (with address at Avenue Blücher 63, 1180 Uccle) and Robert Taub
  •  Date on which the threshold was crossed: July 7, 2021
  •  Threshold that is crossed: 3%
  •  Denominator: 25,002,609
  •  Notified details:

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Robert Taub	2,121,470	2,121,470		8.48%
BMI Estate	0	0		0.00%
Robelga SRL	696,000	696,000		2.78%
Subtotal	2,817,470	2,817,470		11.27%
	TOTAL	2,817,470	0	11.27%	0.00%

• •  Chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.
  •  Additional information:

      1.     On 23 June 2021, MINV SA (former shareholder) was absorbed (merger by absorption) by Robelga SRL.

      2.     The participation of Robelga SRL passed below the 3% threshold. The participation of the group Robelga SRL and Robert Taub stays above the 10% threshold.

3.     BMI Estate is the new name of Romata (mistakenly referred to as “Ronata” in the previous transparency notification).

Together Partnership 

On August 27, 2021, Nyxoah received a transparency notification from Together Partnership following the passive downward crossing of the 10% threshold on July 9, 2021. As of such date, Together held 2,503,500 shares, representing 9.84% of the total number of voting rights on July 9, 2021 (25,437,859).

The notification dated August 27, 2021 contains the following information:

• •  Reason for the notification: passive crossing of a threshold
  •  Notification by: a person notifying alone
  •  Person subject to the notification requirement: Together Partnership (with address at Uitbreidingstraat 10-16, 2600 Berchem)
  •  Date on which the threshold was crossed: July 9, 2021
  •  Threshold that is crossed: 10%
  •  Denominator: 25,437,859
  •  Notified details:

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Together Partnership	2,503,500	2,503,500		9.84%
	TOTAL	2,503,500		9.84%

• •  Chain of controlled undertakings through which the holding is effectively held: Together Partnership is not a controlled entity.

*

*        *

Contact:

Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Attachment

• 2021 09 01 PR Transparency notifications 2021 08 (Together Robelga Taub) (ENG)